HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• COVID-19 and blood cancer: Evolving science on a dangerous comorbidity Jennifer Byrne
• Should therapy for hematologic malignancies be modified to mitigate poor COVID-19 outcomes?
• Clinician burnout: A mental health ‘pandemic within a pandemic’ Bernadette Mazurek Melnyk, PhD, APRN-CNP, FAANP, FNAP, FAAN
• Protecting your time key to work-life balance for women in oncology Talitha Bennett
• Male allies should listen to, respect, seek equality for female oncologists Jennifer Byrne
• One-third of colorectal cancer survival disparities a product of treatment gaps Alexandra (Sasha) Todak
• Pembrolizumab prolongs PFS vs. chemotherapy for certain patients with colorectal cancer Jennifer R. Southall
• Intraperitoneal paclitaxel prolongs survival in gastric cancer with peritoneal metastases Alexandra (Sasha) Todak
• Adjuvant palbociclib fails to improve invasive DFS in high-risk breast cancer Alexandra (Sasha) Todak
• ASCO president aims to shed light on cancer care inequities Jennifer R. Southall
• Financial toxicity a lingering, often unexpected burden for cancer survivors Jennifer Byrne
• Studies contradict earlier findings on blood group and COVID-19 severity, mortality Jennifer Byrne
• More advanced, aggressive breast cancers diagnosed during COVID-19 pandemic Jennifer R. Southall
• Adding bemarituzumab to chemotherapy improves outcomes in certain gastric cancers Jennifer R. Southall
• Adjuvant abemaciclib improves outcomes for certain patients with high-risk breast cancer Mark Leiser
• Data further support role for pembrolizumab plus chemotherapy in breast cancer subset Jennifer R. Southall
• Myeloproliferative neoplasm driver mutations often acquired before birth, in childhood Alexandra (Sasha) Todak
• SY-1425 plus azacitidine induces high response rate in AML subgroup Jennifer R. Southall
• Consolidation treatment improves outcomes in newly diagnosed multiple myeloma Mark Leiser
• Asciminib effective, safe as late-line treatment for chronic-phase CML Jennifer R. Southall
• Sickle cell disease may increase risk for COVID-19 complications, death Alexandra (Sasha) Todak
• Pembrolizumab shows promising OS for previously untreated advanced HCC Alexandra (Sasha) Todak
• US cancer mortality continues to decline at record pace Jennifer R. Southall
• FDA approves Margenza for metastatic HER2-positive breast cancer
• FDA approves Orgovyx, first oral hormone therapy for advanced prostate cancer
• Bristol Myers Squibb withdraws Opdivo for small cell lung cancer indication
• FDA approves Riabni, third biosimilar to Rituxan
• FDA updates safety guidance, labeling requirements for power morcellators
• Oncologist elected to fellowship in Royal College of Physicians of London
• Grant funds research into chemotherapy-induced peripheral neuropathy susceptibility
• Sarah Cannon appoints lung cancer research program director